Publications by authors named "M Meshad"

Claim this Profile
I
Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.
Elizabeth Koselke, Lisa C Kaspin-Powell, Shannon Hough, Joshua Howell, Nicholas J Robert, Michael W Meshad

J Adv Pract Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.
B P Nicholson, D M Paul, K R Hande, Y Shyr, M Meshad

Clin Breast Cancer· July 2000

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.
T M Beck, M York, A Chang, R Navari, W H Harvey, M Meshad

Cancer Invest· August 1997

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
D M Paul, A M Garrett, M Meshad, R D DeVore, L L Porter

Semin Oncol· February 1996

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
L X Cubeddu, K Pendergrass, T Ryan, M York, G Burton, M Meshad

Am J Clin Oncol· April 1994

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis